Denise C. Welsh1, Andrew Danziger2,
Theodore Detwiler2, Hillary Regan2, Joseph J. Lynch2,
Christopher P. Regan2, Donald S. Williams1, Alexandre
Coimbra1
1Imaging, Merck, West Point, Pa, United
States; 2Central Pharmacology, Merck, West Point, Pa, United
States
While
numerous studies have used MRI techniques for studying stroke pathology,
there has been limited use of MR parameters as in vivo markers of novel
treatment efficacy. Here, Gd-enhanced
T1-w and T2-w MR data were used to verify the efficacy of pre- and
post-infarct treatment with a novel KDR kinase inhibitor (KDRi) known to
reduce vascular permeability and therefore, BBB leakage. In line with previously published ex-vivo
data (1), in-vivo MRI results suggest efficacy of KDRi treatment in reducing
BBB leakage and edema formation, as indicated by tissue water content.